FDA approves Lilly's new Alzheimer's drug after delay
The Food and Drug Administration (FDA) on Tuesday approved Eli Lilly’s Alzheimer’s drug, the company announced, clearing the way for another entry into the market of a new class of drugs that moderately slows the disease’s progression.
The agency last month held an advisory panel meeting to scrutinize the safety and effectiveness of the drug, called donanemab, after delaying approval in March.
The decision to require a panel meeting came as a surprise to the company, which submitted its traditional approval application of donanemab to the FDA last year and anticipated getting the green light by early 2024.
FDA’s independent advisers unanimously backed recommending approval.
Donanemab, now marketed as Kisunla, is a monoclonal antibody that targets a brain plaque called amyloid. It’s intended to treat early-stage disease and is administered monthly by intravenous infusion.
The drug will be available in the coming weeks, Lilly said.
According to Lilly, donanemab slowed Alzheimer’s disease progression by 35 percent relative to placebo treatment, in an 18-month clinical trial that enrolled 1,700 patients with early-stage disease. In practical terms, that translated to delaying progression by about four months.
There were serious risks identified in the trial, raising concerns that the risk outweighed the benefit. Three people died after developing serious brain bleeding or swelling.
Anti-amyloid drugs can significantly reduce the levels of a sticky plaque in the brain called amyloid beta, but questions remain about the clinical significance and degree of benefit.
More than 6 million people in the United States are diagnosed with Alzheimer’s, and that number is expected to rise as the population ages. There is no cure, but there are about 1 million people with early-stage disease who could benefit most from the drug.
“This is real progress. Today’s approval allows people more options and greater opportunity to have more time. Having multiple treatment options is the kind of advancement we’ve all been waiting for — all of us who have been touched, even blindsided, by this difficult and devastating disease," Joanne Pike, president and CEO of the Alzheimer's Association said in a statement.
Donanemab is the third amyloid-targeting Alzheimer’s drug to get the green light from FDA since 2021. Biogen and Eisai jointly developed Aduhelm and Leqembi, though Aduhelm was plagued by controversy from the start and was discontinued in January.
Unlike Leqembi, donanemab use can be stopped after amyloid plaque is removed to minimal levels, which Lilly said can result in lower treatment costs and fewer infusions.
The price of each vial of Kisunla is $695.65 Lilly said, which equates to $32,000 for a year. That's more than Leqembi, which costs patients an estimated $26,500 a year. But patients don't stop taking Leqembi.
The actual cost will depend on how long patients take the treatment, though Lilly noted Medicare Part B will cover and provide some reimbursement—patients will be responsible for a 20 percent coinsurance after meeting their deductible.
Updated at 4:06 p.m.
Date: | |
Tag: | FDA |
Topics
Filter
-
CBS News - Top stories
FDA approves new treatment to slow progression of early Alzheimer's
The FDA approved a new Alzheimer's treatment called donanemab on Tuesday. It is designed to help patients in the early stages of the disease. CBS News chief medical correspondent Dr. Jon LaPook explains what to know.FDA -
NBC News - Politics
After immunity ruling, Trump’s hush money sentencing delayed
After the Supreme Court’s landmark immunity decision, the judge overseeing former President Donald Trump’s hush money trial in New York has postponed his sentencing that was scheduled for July 11, moving it to mid-September. NBC’s Laura Jarrett ... -
ABC News - World
Israel approves plans for nearly 5,300 new homes in West Bank settlements
An Israeli anti-settlement monitoring group says the government has approved plans to build nearly 5,300 new homes in settlements in the occupied West BankIsrael -
MarketWatch - Business
Roche to halt lung-cancer drug trial after disappointing data
Roche Holding said it plans to halt a mid- and late-stage clinical study for a combination of drugs to treat lung cancer after it failed to meet the trial’s primary efficacy goals. -
The Guardian - World
England beat New Zealand by five wickets: third women’s cricket ODI – live
Lauren Bell took her first five-for at international level before the brilliant Nat Sciver-Brunt guided England to a 3-0 series win. “Absolutely huhning it down here in Bristol Dan”. That’s the bleak report from Michael Jelley. I’m not sure what ...New Zealand -
CBS News - Top stories
Trump's sentencing delayed in New York conviction following Supreme Court immunity decision
Former President Donald Trump's sentencing for his New York criminal conviction has been delayed after the Supreme Court earlier this week ruled presidents have immunity for official acts while in office. CBS News' Robert Costa explains the ...New York -
ABC News - Tech
Cybersecurity breach could delay court proceedings across New Mexico, public defenders office says
New Mexico's statewide public defenders office says a recent cybersecurity breach could delay some court proceedings across the state -
NBC News - Top stories
Delta flight diverts to New York after passengers are served spoiled food
A Delta flight from Detroit to Amsterdam was diverted to New York’s Kennedy Airport on Wednesday after passengers were served spoiled food, airline officials said.New York -
ABC News - Top stories
Delta flight diverts to New York after passengers are served spoiled food
A Delta flight from Detroit to Amsterdam was diverted to New York’s Kennedy Airport after passengers were served spoiled foodNew York -
The New York Times - Top stories
New York Moves to Clean Up Times Square After a Spate of Crimes
Despite highly publicized attacks, most major offenses are down. But quality-of-life problems tarnish the “Crossroads of the World,” the city says.New York
More from The Hill
-
The Hill - Politics
Yellowstone National Park shooting leaves suspect dead, ranger injured
A shooting at Yellowstone National Park on July Fourth left a park ranger wounded and the suspect dead, according to a release from the National Park Service. There are no active threats to the public, officials said. The shooting took place at ... -
The Hill - Politics
Biden says he's 'not going anywhere,' takes shot at Trump during Fourth of July event
President Biden said he's "not going anywhere" and took a swipe at former President Trump during remarks before service members and military families who had gathered at the White House for a Fourth of July barbecue. Biden spoke for about four ...Joe Biden -
The Hill - Politics
Saks Fifth Avenue parent to buy Neiman Marcus Group for $2.65 billion
Saks Fifth Avenue parent company HBC announced Thursday a $2.65 billion deal to acquire Neiman Marcus Group, the parent company of Neiman Marcus and Bergdorf Goodman. HBC said that after the deal goes through it will launch Saks Global, which will ... -
The Hill - Politics
Labour Party poised to win UK government after 14 years of Conservative Party rule
The Labour Party is projected to win a landslide victory Thursday evening, ending 14 years of Conservative Party rule in the United Kingdom. Labour is on track to win 410 seats in the British House of Commons, a sizable margin above the 326 seats ...United Kingdom -
The Hill - Politics
Democrats in competitive House races break from Biden
Several Democrats running in competitive House districts this cycle are breaking from President Biden, underscoring growing concerns that the incumbent could be a down-ballot liability following his rocky debate performance in Atlanta last week. ...Joe Biden